中华皮肤科杂志 ›› 2026, Vol. 59 ›› Issue (4): 353-360.doi: 10.35541/cjd.20240364

• 论著 • 上一篇    下一篇

黄连素软膏对特应性皮炎样小鼠皮肤炎症及菌群的影响作用

黄祺甯1    马银超2    王子元2    鲁锡霖   齐映婷1    刘孜妍1    门月华1    初明2    张春雷1   

  1. 1北京大学第三医院皮肤科,北京  100191;2北京大学基础医学院,北京  100191
  • 收稿日期:2024-07-09 修回日期:2026-02-27 发布日期:2026-04-03
  • 通讯作者: 门月华;初明 E-mail:menyuehua@126.com
  • 基金资助:
    北京大学第三医院2022年医院创新转化基金(BYSYZHKC2022120);北京大学医学部“医-X交叉种子基金”项目(BMU2021MX021)

Effects of berberine ointment on skin inflammation and microbiota in an atopic dermatitis-like mouse model

Huang Chinin1, Ma Yinchao2, Wang Ziyuan2, Lu Xilin2, Qi Yingting1, Liu Ziyan1, Men Yuehua1, Chu Ming2, Zhang Chunlei1   

  1. 1Department of Dermatology, Peking University Third Hospital, Beijing 100191, China; 2School of Basic Medical Sciences, Peking University, Beijing 100191, China
  • Received:2024-07-09 Revised:2026-02-27 Published:2026-04-03
  • Contact: Men Yuehua; Chu Ming E-mail:menyuehua@126.com
  • Supported by:
    Peking University Third Hospital 2022 Hospital Innovation Transformation Fund (BYSYZHKC2022120); Central Universities' Basic Research Operating Expenses (BMU2021MX021)

摘要: 【摘要】 目的 探讨外用黄连素软膏对特应性皮炎(AD)样小鼠皮肤炎症和菌群变化的影响。方法 将36只雄性BALB/c小鼠分为6组:空白对照组,模型组,0.01%、0.1%、1%黄连素组和0.03%他克莫司组。除空白对照组外,其余小鼠于双侧耳背用2,4-二硝基氯苯致敏,第1周每周3次(第1、3、5天)致敏,第2、3周每3天维持致敏1次;自第2周起按分组每天给予局部药物治疗,连续2周。末次用药24 h后大体评估皮损情况,处死小鼠后收集耳组织进行苏木精-伊红染色测量耳厚度,并基于16S rRNA进行皮肤菌群测序分析。采用单因素方差分析及Games-Howell法进行统计比较。结果 各黄连素组和他克莫司组的耳厚度均显著低于模型组(P < 0.05)。与模型组对比,1%黄连素组Shannon指数较低(0.70 ± 0.41比1.31 ± 0.10),Simpson指数较高(0.64 ± 0.24比0.35 ± 0.06),差异均有统计学意义(P值分别为0.005、0.015)。0.1%黄连素组的葡萄球菌属丰度(16.68%)低于模型组(47.23%),差异有统计学意义(P < 0.001)。结论 黄连素软膏能减轻AD样小鼠耳部增厚、红肿以及鳞屑等症状,调节耳部皮肤中菌群丰度,抑制葡萄球菌属,为其临床应用提供了理论支持。

关键词: 皮炎, 特应性, 小檗碱, 治疗, 炎症, 皮肤菌群, 葡萄球菌属

Abstract: 【Abstract】 Objective To investigate the effects of topical berberine ointment on skin inflammation and microbial changes in an atopic dermatitis-like mouse model. Methods Thirty-six male BALB/c mice were randomly divided into 6 groups: a blank control group, a model group, 0.01%, 0.1%, and 1% berberine groups, and a 0.03% tacrolimus group. Except for the blank control group, all mice were sensitized with 2,4-dinitrochlorobenzene on the dorsal ears; sensitization was performed three times per week during the first week (on days 1, 3, and 5), followed by once every three days during weeks 2 and 3; from the second week onward, topical treatments were administered daily according to group assignment for two consecutive weeks. Twenty-four hours after the final treatment, skin lesions in mice were grossly evaluated. The mice were then sacrificed, and ear tissues were collected for hematoxylin and eosin staining to measure ear thickness, as well as for microbial 16S rRNA sequencing analysis. Statistical analysis was performed using one-way analysis of variance followed by the Games-Howell test. Results Ear thickness was significantly lower in all the berberine groups and the 0.03% tacrolimus group than in the model group (all P < 0.05). Compared with the model group, the 1% berberine group showed lower Shannon indices (0.70 ± 0.41 vs. 1.31 ± 0.10, P = 0.005) and higher Simpson indices (0.64 ± 0.24 vs. 0.35 ± 0.06, P = 0.015). The relative abundance of Staphylococcus spp. was significantly lower in the 0.1% berberine group (16.68%) than in the model group (47.23%, P < 0.001). Conclusion In the atopic dermatitis-like mouse model, berberine ointment could reduce ear thickening, alleviate erythema and scaling, modulate the abundance of skin microbiota, and inhibit Staphylococcus spp., which provides theoretical support for its clinical application.

Key words: Dermatitis, atopic, Berberine, Therapy, Inflammation, Skin microbiota, Staphylococcus

中图分类号: 


引用本文

黄祺甯 马银超 王子元 鲁锡霖 齐映婷 刘孜妍 门月华 初明 张春雷. 黄连素软膏对特应性皮炎样小鼠皮肤炎症及菌群的影响作用[J]. 中华皮肤科杂志, 2026,59(4):353-360. doi:10.35541/cjd.20240364

Huang Chinin, Ma Yinchao, Wang Ziyuan, Lu Xilin, Qi Yingting, Liu Ziyan, Men Yuehua, Chu Ming, Zhang Chunlei. Effects of berberine ointment on skin inflammation and microbiota in an atopic dermatitis-like mouse model [J]. Chinese Journal of Dermatology, 2026, 59(4): 353-360.doi:10.35541/cjd.20240364